Treatment of Spasmodic Dysphonia with Botulinum Toxin: Clinical Experiences and Research Issues

  • Gayle E. Woodson
  • Thomas Murry
  • Petra Zwirner
  • Michael Swenson


Spasmodic Dysphonia is a disabling speech disorder characterized by excessive contractions of laryngeal muscles. Botulinum toxin has been demonstrated in several clinical trials to be very effective in improving speech in most patients and its clinical use is becoming more widespread. Although the benefits of botulinum toxin treatment are considerable, few patients achieve a totally normal voice and minor side effects are common. Clinical research is needed to determine the factors limiting improvement, to determine the role of adjunctive speech therapy, and to develop treatment protocols which will maximize benefits and diminish side effects.


Botulinum Toxin Essential Tremor Vocal Fold Botulinum Toxin Injection Bilateral Injection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Adams RD, Victor M. Principles of Neurology, 4th ed. New York: McGraw-Hill, 1989: 62–67.Google Scholar
  2. 2.
    Arnold GE. Spastic dysphonia: I. Changing interpretations of a persistent affliction. Logos 1959; 2: 314.Google Scholar
  3. 3.
    Aronson AE, Brown JR, Litin EM, et al. Spastic dysphonia. I. Voice, neurologic, and psychiatric aspects. J Speech Hear Disord 1968; 33: 203–218.PubMedGoogle Scholar
  4. 4.
    Aronson AE, Brown JR, Litin EM, et al. Spastic dysphonia II. Comparison with essential (voice) tremor and other neurologic and psychogenic dysphonias. J Speech Hear Disord 1968; 33: 219–231.PubMedGoogle Scholar
  5. 5.
    Aronson AE, Hartman DE. Adductor spastic dysphonia as a sign of essential (voice) tremor. J Speech Hear Disord 1981; 46: 52–56.PubMedGoogle Scholar
  6. 6.
    Aronson AE. Psychogenic voice disorders: an interdisciplinary approach to detection, diagnosis and therapy. In: Audio Seminars in Speech Therapy. Philadelphia: Saunders, 1973.Google Scholar
  7. 7.
    Blitzer A, Brin M, Fahn S, Lovelace RE. Clinical characteristics of focal laryngeal dystonia: Study of 110 cases. Laryngoscope 1988; 98: 636–640.PubMedCrossRefGoogle Scholar
  8. 8.
    Blitzer A, Brin MF, Stewart C, Aviv J, Fahn, S. Abductor laryngeal dystonia: a series treated with botulinum toxin. Laryngoscope 1992; 102: 163–167.PubMedCrossRefGoogle Scholar
  9. 9.
    Cannito M, Johnson J. Spastic dysphonia: A continuum disorder. J. Commun Dis 1981; 14: 215–223.CrossRefGoogle Scholar
  10. 10.
    Dedo HH. Recurrent laryngeal nerve section for spastic dysphonia. Ann Otol Rhino] Laryngol 1976; 85: 451–59.Google Scholar
  11. 11.
    Ford CN. A multipurpose laryngeal injector device. Otolaryngol Head Neck Surg 1990; 103: 135–137.PubMedGoogle Scholar
  12. 12.
    Freeman F, Cannito MP, Finitzo-Hieber T. Classification of Spasmodic Dysphonia by PerceptualAcoustic-Visual Means. Spastic dysphonia: State of the Art 1984. New York: The Voice Foundation, 1984: 5–13.Google Scholar
  13. 13.
    Ludlow CL, Naunton RF, Sedory MA, Schulz MA, Hallett M. Effects of botulinum toxin injections on speech in adductor spasmodic dysphonia. Neurology 1988; 38:1220-122?Google Scholar
  14. 14.
    Ludlow CL, Hallett M, Sedory SE et al. The Pathophysiology of spasmodic dysphonia and its modification by botulinum toxin. In: Beradelli A, Benecke R, eds. Motor Disturbances I I. London: Academic Press, 1990.Google Scholar
  15. 15.
    Miller RH, Woodson GE, Jancovic J. Botulinum toxin injection of the vocal for spasmodic dysphonia. Arch Otol Laryngol Head Neck Surg 1987; 113: 603–605.CrossRefGoogle Scholar
  16. 16.
    Rabuzzi DD, McCall GN. Spasmodic dysphonia: A clinical perspective. Trans Am Acad Ophthalmol Otolaryngol 1972; 76: 724–728.PubMedGoogle Scholar
  17. 17.
    Robe E, Brulik J, Moore, P. A study of spastic dysphonia. Neurologic and electroencephalographic abnormalities. Laryngoscope 1960; 50: 219–245.Google Scholar
  18. 18.
    Rosenfield DB, Donovan DT, Sulek M, Viswanath NS, Inbody GP, Nudelman HB. Neurologic aspects of spasmodic dysphonia. J Otolaryngology 1990; 19: 231–236.Google Scholar
  19. 19.
    Schaefer S. Neuropathology of spasmodic dysphonia. Laryngoscope 1983; 93: 1183–1204.PubMedGoogle Scholar
  20. 20.
    Truong EE, Rontal M, Rolnick M et al. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia. Laryngoscope 1991; 101: 630–634.CrossRefGoogle Scholar
  21. 21.
    Woodson GE, Zwimer P, Murry T, Swenson M. Use of flexible laryngoscopy to classify patients with spasmodic dysphonia. J Voice 1991; 5: 85–91.CrossRefGoogle Scholar
  22. 22.
    Woodson GE, Murry T, Zwimer P, Swenson M. Assessment of patients with spasmodic dysphonia. J Voice 1992, in press.Google Scholar
  23. 23.
    Zwimer P, Murry T, Swenson M, Woodson G. Acoustic changes in spasmodic dysphonia after botulinum toxin injection. J Voice 1991; 5: 78–84.CrossRefGoogle Scholar
  24. 24.
    Zwimer P, Murry T, Woodson G. Phonatory function of neurologically impaired patients. J Commun Dis 1991; 24: 287–300.CrossRefGoogle Scholar
  25. 25.
    Zwimer P, Murry T, Woodson G. Effects of botulinum toxin therapy in patients with spasmodic dysphonia: Acoustic, aerodynamic, and videoendoscopic findings Laryngoscope 1992; 102: 400406.Google Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • Gayle E. Woodson
    • 1
  • Thomas Murry
    • 1
  • Petra Zwirner
    • 2
  • Michael Swenson
    • 3
  1. 1.Department of Surgery/Division of OtolaryngologyUniversity of California, San Diego School of Medicine and VA Medical Center, San DiegoSan DiegoUSA
  2. 2.HNO KlinikKlinikum GrosshadernMunich 70Germany
  3. 3.Department of NeurosciencesUniversity of California, San Diego School of MedicineSan DiegoUSA

Personalised recommendations